zepbound eli lilly - Search News

Eli Lilly's next-gen obesity drug is 'raising the bar'

Eli Lilly's powerful new weight-loss drug shows dramatic results

In a clinical trial, the new weight-loss medication retatrutide led to "clinically meaningful weight reduction," with the highest dose linked to a 30% reduction in average body weight

· 22h

Eli Lilly says its next gen obesity drug is more powerful than Zepbound and Wegovy

· 3h

Next-gen obesity drug helps patients lose 28% of body weight: Eli Lilly

· 18h

European Regulator Backs Novo Nordisk’s Wegovy Weight-Loss Pill

The European Medicines Agency recommended the approval of Novo Nordisk’s Wegovy weight-loss pill Friday, paving the way for it to become the first tablet to treat obesity in the bloc.

· 20h

European medicines regulator recommends approval for Novo's Wegovy pill

· 1d

New weight-loss shot appears to outperform other obesity drugs on market

· 1d

Experimental Drug Yields Dramatic Weight Loss

Among the heaviest patients in the trial, the results were on par with those seen with gastric bypass surgery, the only effective treatment for most with severe obesity.

· 1d

Scales might be tipping to favor Eli Lilly’s newest experimental weight-loss injection

· 1d

Could Viking Therapeutics Be the Next Eli Lilly?

1don MSN

Lilly’s experimental shot produced 28% weight loss. That beats Zepbound.

The injection is different than Zepbound and Foundayo.

BioSpace

Lilly maintains weight loss leadership as Foundayo, Zepbound keep pounds off after switching

Despite seeing some regain, patients in two trials maintained most of their weight loss after switching to either Foundayo or lower-dose Zepbound from other injectable incretin therapies.

Can Eli Lilly Stock Reach $1800 by 2030? Here Is the Bull Case

Eli Lilly (NYSE:LLY) is growing like a software company. Q1 2026 revenue hit $19.80B, up 55.5% year over year, with Mounjaro at $8.66B (+125%) and Zepbound at $4.16B (+80%). CEO David Ricks told investors “2026 is off to a strong start,

Zepbound vs. Mounjaro For Weight Loss: What’s The Difference?

Mounjaro and Zepbound are two brand-name glucagon-like peptide-1 (GLP-1) medications manufactured by Eli Lilly. Although they contain the same active ingredient, tirzepatide, and may affect blood sugar regulation and weight,

Eli Lilly and its gambit to stay on top of the GLP-1 heap

However, Eli Lilly launched its own weight loss pill, orforglipron, marketed as Foundayo, in April. And the company has another drug candidate, retatrutide, that targets GLP-1 and GIP receptors, as well as glucagon receptors.

From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook

Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand.

Zepbound vs. Wegovy For Weight Loss: What’s The Difference?

If you’re weighing the option of Wegovy versus Zepbound for weight loss, here’s how the two medications compare in terms of effectiveness, side effects, average costs and the best online weight loss medication platforms to buy them.